aTyr Pharma, Inc. (NASDAQ:ATYR) Given Average Recommendation of “Hold” by Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR) has been assigned an average rating of “Hold” from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.6667.

A number of brokerages recently issued reports on ATYR. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Jefferies Financial Group reiterated a “buy” rating on shares of aTyr Pharma in a report on Friday, March 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of aTyr Pharma in a research report on Monday, December 29th.

Institutional Trading of aTyr Pharma

Several large investors have recently added to or reduced their stakes in ATYR. Profund Advisors LLC bought a new position in shares of aTyr Pharma in the 3rd quarter worth about $27,000. California State Teachers Retirement System purchased a new position in aTyr Pharma during the 2nd quarter valued at about $28,000. ADAR1 Capital Management LLC boosted its stake in aTyr Pharma by 35.9% during the fourth quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in aTyr Pharma during the fourth quarter worth about $41,000. Finally, Ameritas Investment Partners Inc. purchased a new stake in aTyr Pharma in the second quarter worth about $45,000. Institutional investors own 61.72% of the company’s stock.

aTyr Pharma Stock Up 6.7%

Shares of aTyr Pharma stock opened at $0.78 on Wednesday. The company’s fifty day simple moving average is $0.87 and its two-hundred day simple moving average is $0.84. aTyr Pharma has a 12-month low of $0.64 and a 12-month high of $7.29. The firm has a market cap of $76.48 million, a PE ratio of -0.99 and a beta of 0.55.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. As a group, sell-side analysts expect that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.